AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31439004 — intervention group
Group type: EXPERIMENTAL
Intervention: VIBRA model (differentiated ART delivery package with drug refills and follow-ups by trained village health workers, and SMS notifications)
Number of subjects: 262
Study 31439004 — intervention group
Group type: COMPARATOR
Intervention: Standard care (collecting ART refills from a clinic, no SMS notifications)
Number of subjects: 262
Study 31439004 — intervention group
Group type: EXPERIMENTAL
Intervention: VIBRA model
Number of subjects: 262
Study 31439004 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 262
Study 27160412 — intervention group
Group type: EXPERIMENTAL
Intervention: THC:CBD oromucosal spray
Number of subjects: 241
Study 27160412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 24845395 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi plus usual care
Number of subjects: 43
Study 24845395 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 43
Study 23538313 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined periprostatic nerve block (PPNB) and perianal‐intrarectal lidocaine‐prilocaine (PILP) cream
Number of subjects: 240
Study 23538313 — intervention group
Group type: EXPERIMENTAL
Intervention: Perianal‐intrarectal lidocaine‐prilocaine (PILP) cream
Number of subjects: 240
Study 23538313 — intervention group
Group type: COMPARATOR
Intervention: Periprostatic nerve block (PPNB)
Number of subjects: 240
Study 20579542 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HDL-C levels
Number of subjects: 625477
Study 20579542 — intervention group
Group type: COMPARATOR
Intervention: Control arms (not specified)
Number of subjects: 625477
Study 18204986 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16978950 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryo-assisted localization (CAL)
Number of subjects: 310
Study 16978950 — intervention group
Group type: COMPARATOR
Intervention: Needle-wire localization (NWL)
Number of subjects: 310
Study 12919654 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticosteroid at a low dosage
Number of subjects: 38
Study 12919654 — intervention group
Group type: COMPARATOR
Intervention: Control group (no glucocorticosteroid)
Number of subjects: 38
Study 12919654 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (with glucocorticosteroid)
Number of subjects: 38
Study 11057000 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbed trials (resistive force of 12 N)
Number of subjects: 6
Study 11057000 — intervention group
Group type: COMPARATOR
Intervention: Non-perturbed trials (baseline)
Number of subjects: 6
Study 11057000 — intervention group
Group type: EXPERIMENTAL
Intervention: Aperture variables (relative moment of final hand closure)
Number of subjects: 6
Study 8956920 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (250 mg, 500 mg, 750 mg, 1,000 mg single oral dose; 250 mg b.i.d. for 3-5 days)
Number of subjects: 12
Study 8956920 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 12
Study 7827348 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin management (infusion pump or split-dose therapy)
Number of subjects: 78
Study 3294081 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum-magnesium antacid (120 mmol/day)
Number of subjects: 89
Study 3294081 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg b.i.d.)
Number of subjects: 89
Study 3294081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 30882520 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 1498
Study 30882520 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 1498
Study 31016613 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide sodium 10 mg
Number of subjects: 100
Study 31016613 — intervention group
Group type: COMPARATOR
Intervention: Leflunomide 10 mg
Number of subjects: 100
Study 27606790 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored education program using touch‐screen computers
Number of subjects: 53
Study 27606790 — intervention group
Group type: COMPARATOR
Intervention: Booklet education
Number of subjects: 53
Study 29028921 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartPilot® View-guided anaesthesia
Number of subjects: 97
Study 29028921 — intervention group
Group type: COMPARATOR
Intervention: Usual practice anaesthesia
Number of subjects: 97
Study 23706433 — intervention group
Group type: EXPERIMENTAL
Intervention: HemoSep device (group 1, n = 52)
Number of subjects: 102
Study 23706433 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (group 2, n = 50)
Number of subjects: 102
Study 21330275 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (6- to 9-month abstinence)
Number of subjects: 1027
Study 21330275 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking
Number of subjects: 1027
Study 19623184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (specific intervention details not available)
Number of subjects: 0
Study 19623184 — intervention group
Group type: COMPARATOR
Intervention: Control arm (specific control details not available)
Number of subjects: 0
Study 17161123 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg mifepristone
Number of subjects: 83
Study 17161123 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg mifepristone
Number of subjects: 83
Study 15079120 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative intercostal nerve blockade with alcohol plus postoperative epidural analgesia with morphine (n=27)
Number of subjects: 57
Study 15079120 — intervention group
Group type: COMPARATOR
Intervention: Postoperative epidural analgesia with morphine only (n=30)
Number of subjects: 57
Study 11199943 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium (valproate) augmentation with haloperidol
Number of subjects: 0
Study 11199943 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol alone (no-augmentation group)
Number of subjects: 0
Study 11199943 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium (valproate) augmentation after 14 days (delayed-augmentation group)
Number of subjects: 0
Study 11199943 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-augmentation group
Number of subjects: 0
Study 8676626 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (1998 mg daily for bodyweight > 60 kg; 1332 mg daily for ≤ 60 kg)
Number of subjects: 455
Study 8676626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 455
Study 8676626 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 455
Study 1737710 — intervention group
Group type: EXPERIMENTAL
Intervention: VA hospital-based team home care (HBHC, N = 85)
Number of subjects: 171
Study 1737710 — intervention group
Group type: COMPARATOR
Intervention: Customary care (N = 86)
Number of subjects: 171
Study 6145189 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiothixene
Number of subjects: 0
Study 6145189 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 30695288 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation antipsychotic prescription
Number of subjects: 674
Study 30695288 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic drug administration
Number of subjects: 674
Study 30695288 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative symptoms (PANSS subscore)
Number of subjects: 674
Study 30695288 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS disorganized factor
Number of subjects: 674
Study 29383596 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) at 5 mg/kg at 0, 2, and 6 weeks, followed by every 8 weeks for 2 years
Number of subjects: 38
Study 29383596 — intervention group
Group type: COMPARATOR
Intervention: Non-Infliximab (non-IFX)
Number of subjects: 38
Study 27629859 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/PI-48w (tenofovir disoproxil fumarate 300 mg/day plus pegylated interferon 180 μg/week for 48 weeks)
Number of subjects: 0
Study 27629859 — intervention group
Group type: COMPARATOR
Intervention: TDF/PI-16w+TDF-32w (tenofovir disoproxil fumarate plus pegylated interferon for 16 weeks, then tenofovir for 32 weeks)
Number of subjects: 0
Study 27629859 — intervention group
Group type: COMPARATOR
Intervention: TDF-120w (tenofovir disoproxil fumarate for 120 weeks)
Number of subjects: 0
Study 27629859 — intervention group
Group type: COMPARATOR
Intervention: PI-48w (pegylated interferon for 48 weeks)
Number of subjects: 0
Study 24991037 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous aerobic exercise training
Number of subjects: 60
Study 24991037 — intervention group
Group type: COMPARATOR
Intervention: Interval aerobic exercise training
Number of subjects: 60
Study 22989707 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine oxytocin use
Number of subjects: 252
Study 22989707 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin discontinuation (DC)
Number of subjects: 252
Study 19604092 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine or Olanzapine (specific dosage not mentioned)
Number of subjects: 129
Study 17544778 — intervention group
Group type: COMPARATOR
Intervention: Focal photocoagulation
Number of subjects: 109
Study 17544778 — intervention group
Group type: COMPARATOR
Intervention: 20‐mg anterior sub‐Tenon injection of triamcinolone
Number of subjects: 109
Study 17544778 — intervention group
Group type: COMPARATOR
Intervention: 20‐mg anterior sub‐Tenon injection followed by focal photocoagulation after 4 weeks
Number of subjects: 109
Study 17544778 — intervention group
Group type: COMPARATOR
Intervention: 40‐mg posterior sub‐Tenon injection of triamcinolone
Number of subjects: 109
Study 17544778 — intervention group
Group type: COMPARATOR
Intervention: 40‐mg posterior sub‐Tenon injection followed by focal photocoagulation after 4 weeks
Number of subjects: 109
Study 14968084 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using verteporfin (Visudyne®)
Number of subjects: 0
Study 14968084 — intervention group
Group type: COMPARATOR
Intervention: Fluorescein angiography
Number of subjects: 0
Study 11403730 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 4-mg gum + cigarette
Number of subjects: 19
Study 11403730 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 4-mg gum + unlit cigarette
Number of subjects: 19
Study 11403730 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum + cigarette
Number of subjects: 19
Study 11403730 — intervention group
Group type: COMPARATOR
Intervention: Nicotine 4-mg gum
Number of subjects: 19
Study 11403730 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups during exercise
Number of subjects: 19
Study 11403730 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant gum plus smoking
Number of subjects: 19
Study 11403730 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study
Number of subjects: 19
Study 9564062 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasless laparoscopy
Number of subjects: 67
Study 9564062 — intervention group
Group type: COMPARATOR
Intervention: Traditional laparoscopy
Number of subjects: 67
Study 9717054 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 0
Study 2488099 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis
Number of subjects: 0
Study 402658 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0
Study 402658 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalorphine
Number of subjects: 0
Study 31665277 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated CABG + ablation
Number of subjects: 7879
Study 30902081 — intervention group
Group type: EXPERIMENTAL
Intervention: J2SI Phase 2 program (n=90)
Number of subjects: 186
Study 30902081 — intervention group
Group type: COMPARATOR
Intervention: Standard service provision (n=96)
Number of subjects: 186
Study 28690088 — intervention group
Group type: EXPERIMENTAL
Intervention: Active screening for metabolic control and diabetes-related complications
Number of subjects: 599
Study 28690088 — intervention group
Group type: COMPARATOR
Intervention: Routine care with similar education
Number of subjects: 599
Study 25473041 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac CT
Number of subjects: 500
Study 25473041 — intervention group
Group type: COMPARATOR
Intervention: Exercise Stress Test (EST)
Number of subjects: 500
Study 23845563 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 11
Study 23845563 — intervention group
Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 11
Study 23845563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 21853762 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored compliance group
Number of subjects: 20
Study 21853762 — intervention group
Group type: COMPARATOR
Intervention: Unmonitored compliance group
Number of subjects: 20
Study 19252110 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 5060
Study 16398726 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony-stimulating factor (G-CSF) mobilized prophylactic granulocyte transfusions (Cohort G)
Number of subjects: 151
Study 16398726 — intervention group
Group type: COMPARATOR
Intervention: Control group (Cohort C)
Number of subjects: 151
Study 15607394 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol septal ablation
Number of subjects: 175
Study 15607394 — intervention group
Group type: COMPARATOR
Intervention: Surgical septal myectomy
Number of subjects: 175
Study 11736861 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone via pMDI
Number of subjects: 21
Study 11736861 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone via Diskus
Number of subjects: 21
Study 11736861 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide via Turbuhaler
Number of subjects: 21
Study 9415540 — intervention group
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation plus low-dose prednisone (TLI-LDP)
Number of subjects: 0
Study 9415540 — intervention group
Group type: COMPARATOR
Intervention: Sham TLI-LDP
Number of subjects: 0
Study 8214746 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl
Number of subjects: 40
Study 8214746 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl
Number of subjects: 40
Study 3316317 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg nickel sulfate taken once a week for 6 weeks
Number of subjects: 24
Study 3316317 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg nickel sulfate taken daily
Number of subjects: 24
Study 30691866 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-Carbohydrate group (PC) - 30g whey protein immediately after exercise and 30g maltodextrin in the afternoon
Number of subjects: 34
Study 30691866 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-Protein group (CP) - 30g maltodextrin immediately after exercise and 30g whey protein in the afternoon
Number of subjects: 34
Study 30021646 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg/100 mL)
Number of subjects: 264
Study 30021646 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl 100 mL)
Number of subjects: 264
Study 23407278 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 279
Study 23407278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 23407278 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) rebounders
Number of subjects: 279
Study 26270306 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay Health Worker (LHW) intervention with 2 educational sessions on CRC screening
Number of subjects: 640
Study 26270306 — intervention group
Group type: COMPARATOR
Intervention: Control group with 2 sessions on healthy eating and physical activity
Number of subjects: 640
Study 22384925 — intervention group
Group type: EXPERIMENTAL
Intervention: Low temperature quantum molecular resonance (QMR) device
Number of subjects: 33
Study 22384925 — intervention group
Group type: COMPARATOR
Intervention: Conventional high temperature electrocautery
Number of subjects: 33
Study 20149586 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support system
Number of subjects: 13
Study 20149586 — intervention group
Group type: COMPARATOR
Intervention: Attending clinicians
Number of subjects: 13
Study 18765433 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg) plus Ezetimibe (10 mg)
Number of subjects: 1873
Study 18765433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1873
Study 15990426 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine prolonged-release capsule (PRC) at doses of 16 or 24 mg/day
Number of subjects: 971
Study 15990426 — intervention group
Group type: COMPARATOR
Intervention: Galantamine prolonged-release capsule (PRC)
Number of subjects: 971
Study 15990426 — intervention group
Group type: COMPARATOR
Intervention: Galantamine PRC
Number of subjects: 971
Study 12723400 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg per day of itraconazole (ITCZ)
Number of subjects: 12
Study 12723400 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg per day of itraconazole (ITCZ)
Number of subjects: 12
Study 10506042 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection with 10 mg lignocaine and 40 mg methylprednisolone
Number of subjects: 60
Study 10506042 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 mg lignocaine)
Number of subjects: 60
Study 10506042 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responders in control group receiving 40 mg methylprednisolone
Number of subjects: 60
Study 9005799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg twice a day for 5 days (IV for first 2 days, then oral for next 3 days)
Number of subjects: 31
Study 9005799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg twice a day for 3 days (oral) + intravenous infusion of 200 mg twice a day for 3 days (for medium disease)
Number of subjects: 31
Study 9005799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg twice a day for 5 days (for chronic carriers)
Number of subjects: 31
Study 9005799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (dosage not specified)
Number of subjects: 31
Study 1848715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethiodized poppy‐seed oil
Number of subjects: 417
Study 1848715 — intervention group
Group type: COMPARATOR
Intervention: Water-soluble media (diatrizoate meglumine, ioxaglate, iohexol)
Number of subjects: 417
Study 1848715 — intervention group
Group type: COMPARATOR
Intervention: Water-soluble media
Number of subjects: 417
Study 1848715 — intervention group
Group type: EXPERIMENTAL
Intervention: All contrast media
Number of subjects: 417
Study 6751704 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide ointment (treated under occlusive dressings for 1 week)
Number of subjects: 119
Study 6751704 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide ointment (treated for 2 weeks)
Number of subjects: 119
Study 6751704 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone-17,21-dipropionate (treated under occlusive dressings for 1 week)
Number of subjects: 119
Study 6751704 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone-17,21-dipropionate (treated for 2 weeks)
Number of subjects: 119
Study 31395484 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone CRI at 0.15 mg kg‐1 minute‐1 for 90 minutes (short CRI)
Number of subjects: 6
Study 31395484 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone CRI at 0.15 mg kg‐1 minute‐1 for 180 minutes (long CRI)
Number of subjects: 6
Study 31395484 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone bolus (3 mg kg‐1) followed by CRI
Number of subjects: 6
Study 31395484 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone CRI (short and long)
Number of subjects: 6
Study 27682229 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based problem-solving treatment (IPST)
Number of subjects: 171
Study 27682229 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 171
Study 26007680 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic administration of antibiotics (Amoxicillin + Metronidazole)
Number of subjects: 36
Study 26007680 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT)
Number of subjects: 36
Study 24213602 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated circulating estradiol (Q5 vs Q1)
Number of subjects: 496
Study 24213602 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated ratio of the 2-hydroxylation pathway (Q5 vs Q1)
Number of subjects: 496
Study 24213602 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated ratio of the 4-hydroxylation pathway (Q5 vs Q1)
Number of subjects: 496
Study 24213602 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ratio of the 2/16-hydroxylation pathways (Q5 vs Q1)
Number of subjects: 496
Study 21123447 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose folic acid (0.4 mg/d)
Number of subjects: 50
Study 21123447 — intervention group
Group type: COMPARATOR
Intervention: Conventional ovarian stimulation without folic acid
Number of subjects: 50
Study 21123447 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild ovarian stimulation
Number of subjects: 50
Study 21123447 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional ovarian stimulation
Number of subjects: 50
Study 20630505 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cystectomy in endometrioma group
Number of subjects: 50
Study 20630505 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cystectomy in nonendometrioma group
Number of subjects: 50
Study 20630505 — intervention group
Group type: COMPARATOR
Intervention: Basal FSH levels (both groups)
Number of subjects: 50
Study 17906344 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning (3 cycles of 30-second angioplasty balloon deflation and 30-second inflation during the first 3 minutes of reperfusion)
Number of subjects: 41
Study 17906344 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 41
Study 17906344 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention applied in the first 3 minutes of reperfusion)
Number of subjects: 41
Study 17906344 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 41